• The top selling prescription drugs by revenue

  Humira tops the list despite growing biosimilar competition, while Opdivo and Keytruda, the new-age checkpoint...
  Read More...

• Will Evofem’s non-hormonal contraceptive Amphora become a game-changer?

  Although non-hormonal contraceptive options are greatly sought-after by women of reproductive age, Amphora may only...
  Read More...

• Pharma Technology Focus: is a memory loss drug on the horizon?

  In this issue: the buzz around esketamine, treatments to target memory loss, cannabis in the...
  Read More...

• Parkinson’s gene therapy development to restart in summer 2019

  Development of the Parkinson’s disease gene therapy that UniQure was previously involved in will be...
  Read More...

• Minerva to explore therapy in treatment-naïve schizophrenia and more

  Minerva Neurosciences’ MIN-101 (roluperidone) is being considered for a future trial in treatment-naïve schizophrenia patients...
  Read More...

• Weighing national security vs foreign investment as Chinese funding of US bio/pharma soars

  The EU and Canada are taking opposite approaches to national security and foreign investment, as...
  Read More...

• Pharma Technology Focus: the absence of antivenom in pharma

  In this issue: addressing the issue of snake bites and antivenom, the medicinal potential of...
  Read More...

• Clinical development and access issues in rare diseases

  The second day of the Orphan Drugs and Rare Diseases 2019 Conference focused on different...
  Read More...

• AAD 2019: S. aureus discussed as biomarker for atopic dermatitis

  New data from trials testing the efficacy and safety of Asana Bioscience’s ASN002, the first...
  Read More...

• Christensella: the key to unlocking gut microbiome-based drug discovery?

  LNC Therapeutics recently signed an agreement with Cornell University for its Christensenella patent, a recently...
  Read More...